Posted by SLS on October 29, 2006, at 23:18:59
In reply to Re: Correction... » SLS, posted by theo on October 29, 2006, at 19:49:45
> So is Abilify least likely to cause tardive dyskensia than other AP's?
I'm not sure. Despite its high binding affinity at D2 receptors, I think theoretical arguments can be made in the affirmative based on its partial agonist properties. However, I would hesitate to make any recommendations. The drug hasn't been around long enough to be certain.
At this point, there may only be one reported incident on Medline:
1: CNS Spectr. 2006 Jun;11(6):435-9.
Aripiprazole-related tardive dyskinesia.
* Maytal G,
* Ostacher M,
* Stern TA.Psychiatric Consultation Service, Massachusetts General Hospital, Boston, MA 02114, USA. gmaytal@partners.org
The low prevalence of extrapyramidal symptoms associated with atypical antipsychotics has led to their widespread use during the past decade. Aripiprazole, the newest medication in this class, has been associated with extrapyramidal symptoms (eg, akathisia) and with improvement of tardive dyskinesia (TD), but to date it has not been associated with the development of TD. We report a case of TD associated with the use of aripiprazole 15 mg/day for 18 months for refractory depression. Symptoms of TD resolved within several weeks of discontinuation of aripiprazole.
PMID: 16816781 [PubMed - indexed for MEDLINE]
- Scott
poster:SLS
thread:698159
URL: http://www.dr-bob.org/babble/20061028/msgs/698936.html